Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

946 ARTÍCULOS , VIENDO DEL 901 AL 915

TREM2 and sTREM2 in Alzheimer's disease: from mechanisms to therapies

Zhang L, Xiang X, Li Y, Bu G, Chen XF.

Mol Neurodegener. 2025 Apr 17;20(1):43. doi: 10.1186/s13024-025-00834-z.

Pathogenesis of comorbid epilepsy in Alzheimer's disease and use of perampanel, an AMPA receptor inhibitor

Kuzuya A, Ohara T, Akamatsu N.

Expert Rev Neurother. 2025 Dec;25(12):1399-1409. doi: 10.1080/14737175.2025.2581758. Epub 2025 Oct 30.

Alzheimer, Parkinson, dementia, and phytochemicals: insight review

Can B, Sanlier N.

Crit Rev Food Sci Nutr. 2025;65(9):1706-1728. doi: 10.1080/10408398.2023.2299340. Epub 2024 Jan 8.

The Neuro-Healing Frontier: Alpha-Mangostin's Potential in Alzheimer's and Parkinson's Treatment

Goyal A, Agrawal N, Agrawal N, Verma A, Solanki K, Yadav HN.

Comb Chem High Throughput Screen. 2025;28(12):1989-1999. doi: 10.2174/0113862073311357240626103752.

Telemedicine in Alzheimer's disease and other dementias: Where we are?

Angelopoulou E, Papageorgiou SG.

J Alzheimers Dis. 2025 Jan;103(1):3-18. doi: 10.1177/13872877241298295. Epub 2024 Dec 5.

"Current and emerging drug therapies in Alzheimer's disease: A pathophysiological Perspective"

Aparajita A, Jain U, Srivastava P.

Neuroscience. 2025 Jan 26;565:499-518. doi: 10.1016/j.neuroscience.2024.11.078. Epub 2024 Dec 9.

Targeting tau in Alzheimer's and beyond: Insights into pathology and therapeutic strategies

Singh S, Khan S, Shahid M, Sardar M, Hassan MI, Islam A.

Ageing Res Rev. 2025 Feb;104:102639. doi: 10.1016/j.arr.2024.102639. Epub 2024 Dec 16.

Ginsenosides Rg1, Rb1 and rare ginsenosides: Promising candidate agents for Parkinson's disease and Alzheimer's disease and network pharmacology analysis

Jiang M, Chi J, Qiao Y, Wang J, Zhang Z, Liu J, Sheng X, Yuan L.

Pharmacol Res. 2025 Feb;212:107578. doi: 10.1016/j.phrs.2025.107578. Epub 2025 Jan 3.

Beyond amyloid plaque, targeting α-synuclein in Alzheimer disease: The battle continues

Al-Kuraishy HM, Sulaiman GM, Mohammed HA, Al-Gareeb AI, Albuhadily AK, Ali AA, Abu-Alghayth MH.

Ageing Res Rev. 2025 Mar;105:102684. doi: 10.1016/j.arr.2025.102684. Epub 2025 Feb 4.

Role of OX/OXR cascade in insomnia and sleep deprivation link Alzheimer's disease and Parkinson's disease: Therapeutic avenue of Dual OXR Antagonist (DORA)

Panda SP, Sinha S, Kesharwani A, Kumar S, Singh M, Kondepudi GM, Samuel A, Sanghi AK, Thapliyal S, Chaubey KK, Guru A.

Biochem Pharmacol. 2025 Mar;233:116794. doi: 10.1016/j.bcp.2025.116794. Epub 2025 Feb 5.

Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer's Disease and Other Neurological Disorders

Almutary AG, Begum MY, Siddiqua A, Gupta S, Chauhan P, Wadhwa K, Singh G, Iqbal D, Padmapriya G, Kumar S, Kedia N, Verma R, Kumar R, Sinha A, Dheepak B, Abomughaid MM, Jha NK.

Mol Neurobiol. 2025 Jun;62(6):7975-7997. doi: 10.1007/s12035-024-04654-y. Epub 2025 Feb 17.

Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations

López-García P, Tejero-Ojeda MM, Vaquero ME, Carrión-Vázquez M.

Prog Neurobiol. 2025 Apr;247:102734. doi: 10.1016/j.pneurobio.2025.102734. Epub 2025 Feb 28.

The role of semaphorin 3A in the pathogenesis and progression of Alzheimer's disease and other aging-related diseases: A comprehensive review

Yuan J, Huang R, Nao J, Dong X.

Pharmacol Res. 2025 May;215:107732. doi: 10.1016/j.phrs.2025.107732. Epub 2025 Apr 11.

RNA-Based Therapies for Neurodegenerative Diseases Targeting Pathogenic Proteins

Rabbani SA, El-Tanani M, Sharma S, El-Tanani Y, Kumar R, Saini M, Yadav M, Khan MA, Parvez S.

Eur J Neurosci. 2025 Apr;61(8):e70110. doi: 10.1111/ejn.70110.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias